Why the study?
Does elimination of cyclosporine A improve health-related quality-of-life in kidney transplant patients on sirolimus-based therapy?
Does elimination of cyclosporine A improve health-related quality-of-life in kidney transplant patients on sirolimus-based therapy?
Early elimination of cyclosporine A from a sirolimus-based regimen improves fatigue, vitality, and appearance-related quality of life in kidney transplant recipients.
This is the authors' abstract. We don't add key points for this paper.
BACKGROUND: This study compared 2-year health-related quality-of-life (HRQL) outcomes of sirolimus (SRL)-treated kidney transplant patients after elimination of cyclosporine A (CsA) to patients continuing on a combined CsA and SRL regimen. METHODS: A randomized, open-label, clinical trial was performed in Europe, Australia, and Canada. Four hundred thirty kidney transplant patients were randomly assigned to sirolimus plus steroids (ST) (n=215) or SRL and CsA+ST (n=215) therapy after 3 months of combined SRL+CsA+ST treatment. HRQL was measured using the Kidney Transplant Questionnaire (KTQ) and the SF-36 Health Survey at month 3 (time of randomization) and months 12 and 24 after transplantation. Repeated-measures analysis of covariance was used to evaluate treatment differences in HRQL scores over the 2-year period. RESULTS: HRQL scores were available for 361 (86%) eligible study patients. Statistically significant treatment-by-assessment time interactions, favoring SRL+ST, were found on KTQ Fatigue (P=0.0158) and Appearance scores (P=0.0007). No treatment differences were observed in KTQ Physical Symptom, Uncertainty-Fear, and Emotion scores. Statistically significant treatment-by-assessment time interactions were observed for SF-36 Vitality scores (P=0.0203) but not other SF-36 scores (P>0.05). For Vitality scores, the SRL+ST group remained stable (mean, 0.4-point change) from month 3 to month 24 compared with decreases in the SRL+CsA+ST group (mean, -6.5-point change). CONCLUSIONS: SRL-based therapy with early elimination of CsA results in fewer appearance-related problems, less fatigue, and better vitality compared with continuous treatment with SRL, CsA, and ST.
Answers are grounded in this paper and cite their sources.
Supports early cyclosporine elimination in sirolimus regimens for kidney transplant QoL gains; extends RCT evidence to fatigue and vitality domains.
No takes yet. Share an insight, caveat, or question.
Oberbauer et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: